<DOC>
	<DOC>NCT02559960</DOC>
	<brief_summary>This registry aims to monitor the safety of Breviscapine Powder-Injection and to identify the potential risk factors for the adverse drug reactions.</brief_summary>
	<brief_title>Post-marketing Safety Surveillance of Breviscapine Powder-Injection : a Registry Study</brief_title>
	<detailed_description>Breviscapine Powder-Injection is a kind of natural compound injection with high purity of Scutellarin-Na (over 98%). It's a popular drug for ischemic diseases, as cerebral ischemic stroke, coronary heart disease or angor pectoris. However, more and more case reports about the adverse drug events of Chinese medicine injections extracted from Dengzhanhua (herba erigernotis) (Breviscapine is one of the most common compounds in it) have been reported in recent 10 years. Therefore, this registry of Breviscapine Powder-Injection aims to monitor the safety of Breviscapine Powder-Injection and to identify the potential risk factors for the adverse drug reactions.</detailed_description>
	<mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
	<mesh_term>Anaphylaxis</mesh_term>
	<criteria>Patients who use Breviscapine PowderInjection in the monitoring departments of centain hospitals</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>